OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
Paul Loubet, Linda Wittkop, Läétitia Ninove, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 388.e1-388.e8
Open Access | Times Cited: 18
Paul Loubet, Linda Wittkop, Läétitia Ninove, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 388.e1-388.e8
Open Access | Times Cited: 18
Showing 18 citing articles:
The immune response to SARS-CoV-2 in people with HIV
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 36
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 36
Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
Omid Rezahosseini, Sebastian Rask Hamm, Line Dam Heftdal, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 12
Omid Rezahosseini, Sebastian Rask Hamm, Line Dam Heftdal, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 12
Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis
Qian Zhou, Furong Zeng, Yu Meng, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Qian Zhou, Furong Zeng, Yu Meng, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Complications virales des biothérapies/thérapies ciblées anti-inflammatoires
Lionel Piroth, Florian Moretto, Thibault Sixt, et al.
La Revue de Médecine Interne (2025)
Open Access
Lionel Piroth, Florian Moretto, Thibault Sixt, et al.
La Revue de Médecine Interne (2025)
Open Access
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Paul Loubet, Iliès Benotmane, Slim Fourati, et al.
Infectious Diseases and Therapy (2025)
Open Access
Paul Loubet, Iliès Benotmane, Slim Fourati, et al.
Infectious Diseases and Therapy (2025)
Open Access
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, et al.
Journal of Endocrinological Investigation (2025)
Open Access
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, et al.
Journal of Endocrinological Investigation (2025)
Open Access
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV
Yi Wang, Jianhua Li, Wenhui Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Yi Wang, Jianhua Li, Wenhui Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 4
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 4
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Christoph D. Spinner, Samira Bell, Hermann Einsele, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 666-719
Open Access | Times Cited: 1
Christoph D. Spinner, Samira Bell, Hermann Einsele, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 666-719
Open Access | Times Cited: 1
Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis
Tian-Yu Zhao, Zongxing Yang, Yuxia Wu, et al.
Epidemiology and Infection (2023) Vol. 151
Open Access | Times Cited: 3
Tian-Yu Zhao, Zongxing Yang, Yuxia Wu, et al.
Epidemiology and Infection (2023) Vol. 151
Open Access | Times Cited: 3
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer patients: Short Review
Ananda Rodilla, Sooyun Caroline Tavolacci, Jazz Cagan, et al.
(2023)
Open Access | Times Cited: 1
Ananda Rodilla, Sooyun Caroline Tavolacci, Jazz Cagan, et al.
(2023)
Open Access | Times Cited: 1
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
Ananda M. Rodilla, Sooyun Caroline Tavolacci, Jazz Cagan, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 969-969
Open Access | Times Cited: 1
Ananda M. Rodilla, Sooyun Caroline Tavolacci, Jazz Cagan, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 969-969
Open Access | Times Cited: 1
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study—ANRS0001s COV-POPART
Paul Loubet, Jean‐Daniel Lelièvre, Alexis François, et al.
International Journal of Infectious Diseases (2024) Vol. 146, pp. 107110-107110
Open Access
Paul Loubet, Jean‐Daniel Lelièvre, Alexis François, et al.
International Journal of Infectious Diseases (2024) Vol. 146, pp. 107110-107110
Open Access
Immunogenicity of SARS ‐CoV ‐2 vaccines in patients treated with chronic double filtration plasmapheresis
Emilie Pambrun, Paul Loubet, Thomas Fourneron, et al.
Journal of Clinical Apheresis (2024) Vol. 39, Iss. 3
Open Access
Emilie Pambrun, Paul Loubet, Thomas Fourneron, et al.
Journal of Clinical Apheresis (2024) Vol. 39, Iss. 3
Open Access
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
Mathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Mathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta- analysis
Qian Zhou, Furong Zeng, Yu Meng, et al.
Research Square (Research Square) (2023)
Open Access
Qian Zhou, Furong Zeng, Yu Meng, et al.
Research Square (Research Square) (2023)
Open Access
Les vaccins à ARN messager anti-Covid-19
Jacques Reynes
Actualités Pharmaceutiques (2023) Vol. 62, Iss. 629, pp. S11-S16
Closed Access
Jacques Reynes
Actualités Pharmaceutiques (2023) Vol. 62, Iss. 629, pp. S11-S16
Closed Access
